
Inogen (INGN) Stock Forecast & Price Target
Inogen (INGN) Analyst Ratings
Bulls say
Inogen Inc is focusing on enhancing growth through increased synergies across its sales channels and revitalizing its direct-to-consumer business while strengthening B2B relationships. The company has formed a partnership with Yuwell to penetrate the Chinese COPD market, which is approximately ten times larger than the U.S. market, indicating substantial long-term growth potential. Additionally, portable oxygen concentrators (POCs) are projected to capture 58% of the market within the next five years, further supporting a positive outlook for Inogen's operational performance and revenue generation.
Bears say
Inogen Inc has experienced a significant decline in sales across its business-to-business (B2B) and direct-to-consumer (DTC) channels, with reported decreases of 17% and 28%, respectively, in 2023. This downturn is attributed to a transition of patients from higher-paying Medicare plans to lower-reimbursing private insurance options, such as Medicare Advantage, along with an increasing number of “capped” patients whose Medicare coverage ends after 36 months. Additionally, the company has struggled with profitability due to an oversized sales force, which has compounded the negative financial outlook despite previous revenue growth.
This aggregate rating is based on analysts' research of Inogen and is not a guaranteed prediction by Public.com or investment advice.
Inogen (INGN) Analyst Forecast & Price Prediction
Start investing in Inogen (INGN)
Order type
Buy in
Order amount
Est. shares
0 shares